Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents.

Patel, Sunny; Steen, Dylan

Patel, Sunny; Steen, Dylan.

Affiliation

Patel S; University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA. patel2sy@mail.uc.edu.
Steen D; University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA. Dylan.Steen@uc.edu.

J Thromb Thrombolysis ; 41(2): 285-92, 2016 Feb.

Article in En | MEDLINE | ID: mdl-26374107

Subject(s)

Anticoagulants; Antidotes; Drug Approval; Animals; Anticoagulants/adverse effects; Anticoagulants/pharmacokinetics; Anticoagulants/therapeutic use; Antidotes/adverse effects; Antidotes/pharmacokinetics; Antidotes/therapeutic use; Biomarkers; Drug Approval/legislation & jurisprudence; Drug Approval/methods; Humans; United States; United States Food and Drug Administration

Key words

Antidote; Drug approval; Novel oral anticoagulant; Reversal agent

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Approval / Anticoagulants / Antidotes Type of study: Prognostic_studies Limits: Animals / Humans Country/Region as subject: America do norte Language: En Journal: J Thromb Thrombolysis Journal subject: ANGIOLOGIA Year: 2016 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google